Stacy L. Moulder, M.D., M.S.C.I.
Department of Breast Medical Oncology, Division of Cancer Medicine
Research Interests
Early Drug Development Clinical Trial Design Determining Pathways of Drug Resistance in Breast Cancer
Click here for the most up-to-date list of Dr. Moulder's publications.
Education & Training
Degree-Granting Education
| 2002 | Vanderbilt University, Nashville, TN, USA, MS, Masters of Science in Clinical Investigation |
| 1995 | University of Mississippi School of Medicine, Jackson, MS, USA, MD, Medicine |
| 1990 | Mississippi State University, Jackson, MS, USA, BS, Chemistry |
Postgraduate Training
| 1998-2001 | Clinical Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN |
| 1995-1998 | Internship and Residency, Internal Medicine, University of Mississippi Medical Center, Jackson, MS |
Board Certifications
| 2002 | American Board of Internal Medicine, Medical Oncology |
| 1998 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2017
Administrative Appointments/Responsibilities
Co-Program Leader, "Learning From the Patient", Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Co-Program Leader, Moon Shots Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Chief, Section of Clinical Research and Drug Development, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017
Honors & Awards
| 2002 | Career Development Award, American Society of Clinical Oncology |
| 2001 | Fellowship Award, American Association for Cancer Research |
| 2001 | Trainee Travel Award, American Society of Clinical Investigation |
| 2001 | Merit Award, American Society of Clinical Oncology |
| 2001 | Star Fellow Award, Vanderbilt Hematology Oncology |
| 2000 | Star Fellow Award, Vanderbilt Hematology Oncology |
| 1998 | Harry Joyce Fellowship, Vanderbilt University Medical Center |
| 1994 | Associated Student Body Vice President, University of Mississippi School of Medicine |
| 1992 | Medical Student Research Fellowship, University of Mississippi Medical Center |
Selected Publications
Peer-Reviewed Articles
- Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004-2009, 2017. e-Pub 2017. PMID: 28819400.
- Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast cancer. Clin Cancer Res 22(1):26-33, 2016. e-Pub 2015. PMID: 26286912.
- Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 2015. e-Pub 2015. PMID: 26348887.
- Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33(4):890-4, 2015. e-Pub 2015. PMID: 25947565.
- DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 21(13):2911-5, 2015. e-Pub 2015. PMID: 25712686.
- Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat 152(2):347-56, 2015. e-Pub 2015. PMID: 26109346.
- Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget 6(15):12890-908, 2015. e-Pub 2015. PMID: 25973541.
- Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
- Abouharb S, Moulder S. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy. Curr Oncol Rep 17(3):431, 2015. PMID: 25691085.
- Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2015. e-Pub 2014. PMID: 25323060.
- Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer 15(1):442, 2015. e-Pub 2015. PMID: 26021831.
- Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2(6):576-80, 2015. e-Pub 2015. PMID: 26244164.
- de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I Unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
- Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple negative breast cancer patients treated at MD Anderson Cancer Center in Phase I Trials: Improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
- Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res 20(20):5265-71, 2014. e-Pub 2014. PMID: 25172932.
- Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 2014. e-Pub 2014. PMID: 25038877.
- Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
- Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
- Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
- Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice. Oncologist 19(5):453-8, 2014. e-Pub 2014. PMID: 24710307.
- Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
- Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 2014. PMID: 24912489.
- Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer 120(6):894-900, 2014. e-Pub 2013. PMID: 24258799.
- Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
- Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
- Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 2013. e-Pub 2013. PMID: 23907406.
- Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: Final results of a phase I trial. Clin Cancer Res 19(19):5474-84, 2013. PMID: 24089446.
- Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res 19(17):4824-31, 2013. e-Pub 2013. PMID: 23873691.
- Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 31(4):918-26, 2013. e-Pub 2012. PMID: 23179336.
- Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol 31(20):e360-3, 2013. e-Pub 2013. PMID: 23733774.
- Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 2013. e-Pub 2012. PMID: 23053261.
- Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 2013. e-Pub 2012. PMID: 23242617.
- Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 3(12):1566-75, 2012. PMID: 23248156.
- Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the anti-angiogenic antibody bevacizumab and the mTOR / hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin. Clin Cancer Res 18(20):5796-805, 2012. e-Pub 2012. PMID: 22927482.
- Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs 30(5):1942-9, 2012. e-Pub 2011. PMID: 21931969.
- Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 2012. e-Pub 2011. PMID: 22006179.
- Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 18(10):2922-9, 2012. e-Pub 2012. PMID: 22452943.
- Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
- Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11(2):308-16, 2012. e-Pub 2011. PMID: 22203732.
- Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal Doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840-6, 2011. e-Pub 2011. PMID: 21890452.
- Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128(3):783-94, 2011. e-Pub 2011. PMID: 21655990.
- Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol 29(19):e572-5, 2011. e-Pub 2011. PMID: 21482991.
- Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel in cancer patients with predominant hepatic metastases: Toxicity, pharmacokinetics, and activity. Mol Cancer Ther 10(7):1300-7, 2011. e-Pub 2011. PMID: 21571911.
- Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
- Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 10(1):209-17, 2011. PMID: 21220503.
- Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 2010. e-Pub 2010. PMID: 20204368.
- Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28(5):634-40, 2010. e-Pub 2009. PMID: 19499186.
- Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9(5):1120-7, 2010. e-Pub 2010. PMID: 20423993.
- Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2010. PMID: 20052721.
- Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 119(3):663-71, 2010. PMID: 20012354.
- Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 10(1):46-51, 2010. PMID: 20133258.
- Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin e can bypass letrozole-induced g1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16(4):1179-90, 2010. e-Pub 2010. PMID: 20145171.
Invited Articles
- Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol 23 Suppl 10:x231-6, 2012. PMID: 22987968.
- Moulder SL. Does the PI3K pathway play a role in basal breast cancer?. Clin Breast Cancer 10:S66-71, 2010. PMID: 21115424.
- Moulder SL. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 6(6):821-30, 2010. PMID: 21118040.
- Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 10:S30-40, 2010. PMID: 20805063.
Grant & Contract Support
| Title: | The use of DNA microarray to determine pathways of metastasis, immune modulation and resistance to therapy in breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Using DNA microarray to determine future targets for breast cancer therapy |
| Funding Source: | Business and Professional Women of Texas |
| Role: | Principal Investigator |
| Title: | A single arm phase II study of gemcitabine and irinotecan in patients with metastatic breast cancer |
| Funding Source: | National Comprehensive Cancer Network (NCCN) |
| Role: | Principal Investigator |
| Title: | Targeting the EGF family of receptors for breast cancer therapy |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Vanderbilt-Ingram Cancer Center Lung SPORE pilot project: Investigating endothelial cell precursors as potential therapeutic targets in lung cancer |
| Funding Source: | Vanderbilt-Ingram Cancer Center |
| Role: | Principal Investigator |
| Title: | Role of circulating endothelial cell precursors in tumor vascular formation |
| Funding Source: | American Association of Cancer Research and American Society of Clinical Oncology |
| Role: | Principal Investigator |
| Title: | LMW-E, a novel indicator of letrozole resistance in breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Investigator |
| Title: | Targeting the cell cycle in triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Validation and implementation of genomic testing for chemotherapy and endocrine sensitivity |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Investigator |
| Title: | Southwest Early Clinical Trials (SECT) Consortium |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Proposal for a partnership between the Translational Breast Cancer Research Consortium and the Susan G. Komen for the Cure Foundation |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Principal Investigator |
| Title: | Women’s triple-negative first-line study: A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT), including a lead in cohort to establish activity in patients with metastatic TNBC |
| Funding Source: | National Comprehensive Cancer Network (NCCN) |
| Role: | Principal Investigator |
| Title: | A randomized clinical trial platform with translational studies to overcome resistance in triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Translational Breast Cancer Research Consortium Infrastructure Support |
| Funding Source: | Johns Hopkins University |
| Role: | Principal Investigator-MDACC |
| Title: | Neoadjuvant triaging and therapeutic platform for treatment of localized triple negative breast cancer (TNBC) |
| Funding Source: | UT MD Anderson Cancer Center (Internal Funding: Women's Cancer Moonshot Breast) Annual Renewal |
| Role: | Principal Investigator |
| Title: | Moon Shot: Breast Cancer |
| Funding Source: | Still Water Foundation |
| Role: | Principal Investigator |
| Title: | A phase Ib, open-label study to assess the safety and tolerability of ONT-380 combined with Capecitabine and Trastuzumab, alone and in combination with HER2+ metastatic breast cancer |
| Funding Source: | Seattle Genetics, Inc |
| Role: | Principal Investigator |
| Title: | A phase 1, multi-center, non-randomized open label, dose escalation design study to characterize safety, toleraility, pharmacokinetics and maximum tolerated dose of BAY 1125976 in subjects with advanced solid tumors |
| Funding Source: | Bayer Pharma AG |
| Role: | Principal Investigator |
| Title: | Investigating the functional impact of TP53 mutations in triple negative breast cancer |
| Funding Source: | Oregon Health and Science University |
| Role: | Co-Investigator |
| Title: | Mesenchymal triple-negative breast cancer (TNBC): Identifying a diagnostic tool |
| Funding Source: | Cedars -Sinai Medical Center |
| Role: | Mentor |
| Title: | Feasibility, validation and implementation of genomic testing for chemotherapy and endocrine sensitivity of HER2 negative primary invasive breast cancer (Clinical Stage I to III) |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Principal Investigator |
| Title: | ARTEMIS: A robust TNBC evaluation framework to improve survival |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Institutional Funds: Breast Moonshot |
| Role: | Principal Investigator |
| Title: | An open-label, Phase I/II, dose escalation study evaluating the safety and tolerability of GDC-0032 in patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive breast cancer |
| Funding Source: | Genentech, Inc |
| Role: | Principal Investigator |
| Title: | Phase II, randomized, double-blinded, controlled study of ONT-80 vs. Placebo in combination with capecitabine and trastuzumab in patients with prepreated unresectable locally advanced or metastatic HER2+ breast carcinoma |
| Funding Source: | Cascadian Therapeutics |
| Role: | Co-Investigator |
| Title: | A randomized multicenter, double-blind Phase III study of Pd-0332991 with (Oral Cdk 4/6 Inhibitor) plus letrozole vs. placebo plus letrozole for the treatment of postmenopausal women with ER (+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease |
| Funding Source: | Pfizer, Inc |
| Role: | Principal Investigator |
| Title: | Task Order: Translational Breast Cancer Research Consortium Infrastructure Support (Annual Renewal) |
| Funding Source: | John Hopkins University |
| Role: | Principal Investigator |